Wall Street Zen Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"

Key Points

• Wall Street Zen upgraded Precigen from “buy” to “strong-buy.” Analyst views are mixed overall, with MarketBeat reporting a “Moderate Buy” consensus and a $13.50 average price target.
• Precigen reported quarterly revenue of $74.15 million and EPS of $0.08, both above the cited consensus estimates; revenue rose sharply year over year.
• Recent analyst actions include HC Wainwright raising its price target to $18, while company insiders sold a combined 235,000 shares worth about $1.75 million over the last quarter.

Precigen (NASDAQ:PGEN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Sunday, Wall Street Zen reports.

Several other brokerages also recently commented on PGEN. Zacks Research downgraded Precigen from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 5th. Raymond James Financial set a $12.00 target price on shares of Precigen in a report on Thursday. Citigroup reissued a "market outperform" rating on shares of Precigen in a report on Thursday. B. Riley Financial initiated coverage on shares of Precigen in a research report on Friday, September 25th. They set a "buy" rating and a $12.00 price target for the company. Finally, HC Wainwright upped their price target on shares of Precigen from $14.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $13.50.

Precigen Price Performance

Precigen stock opened at $4.47 on Friday. Precigen has a one year low of $3.04 and a one year high of $8.98. The business has a fifty day moving average price of $6.98 and a 200-day moving average price of $5.28. The company has a debt-to-equity ratio of 1.12, a current ratio of 5.58 and a quick ratio of 3.89. The firm has a market capitalization of $1.59 billion, a P/E ratio of 44.70 and a beta of 1.01.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Precigen had a return on equity of 57.93% and a net margin of 15.55%. The company had revenue of $74.15 million during the quarter, compared to analysts' expectations of $71.55 million. During the same period in the previous year, the business earned ($1.06) earnings per share. The firm's quarterly revenue was up 2437.6% compared to the same quarter last year. As a group, equities research analysts forecast that Precigen will post 0.27 EPS for the current year.

Insider Activity

In related news, Director Jeffrey B. Kindler sold 185,000 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total value of $1,376,400.00. Following the completion of the sale, the director owned 17,100 shares in the company, valued at $127,224. The trade was a 91.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Rutul R. Shah sold 34,658 shares of the company's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $7.50, for a total value of $259,935.00. Following the completion of the sale, the chief operating officer directly owned 465,012 shares of the company's stock, valued at approximately $3,487,590. This represents a 6.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 235,000 shares of company stock worth $1,751,400 over the last quarter. Corporate insiders own 41.40% of the company's stock.

Institutional Investors Weigh In On Precigen

Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in shares of Precigen by 708.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 459,783 shares of the biotechnology company's stock valued at $3,936,000 after purchasing an additional 402,901 shares during the last quarter. Penn Capital Management Company LLC purchased a new stake in Precigen during the third quarter valued at about $679,000. Verus Capital Partners LLC purchased a new stake in Precigen during the third quarter valued at about $132,000. Calamos Advisors LLC purchased a new stake in Precigen during the third quarter valued at about $2,631,000. Finally, Commonwealth Equity Services LLC grew its stake in shares of Precigen by 5.9% during the third quarter. Commonwealth Equity Services LLC now owns 52,532 shares of the biotechnology company's stock valued at $450,000 after buying an additional 2,909 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.

Key Headlines Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for Precigen across Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. HC Wainwright estimates and rating
• Positive Sentiment: Citizens JMP raised its price target from $11 to $12 and reiterated a Market Outperform rating, adding to the bullish analyst outlook. Citizens JMP price target
• Positive Sentiment: Precigen’s Q3 revenue of $74.1 million topped the cited FactSet estimate of $71.5 million. The reported $0.08 per-share earnings beat some estimates but fell short of the higher Zacks consensus, making the earnings picture mixed. Q3 revenue results
• Negative Sentiment: A valuation analysis argues that PGEN may already be fully priced based on current earnings, which could limit further upside if future growth does not meet expectations. Precigen valuation analysis

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen's pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.